Zacks Rating on Exelixis (EXEL)

Exelixis (EXEL) : 5 analysts are covering Exelixis (EXEL) and their average rating on the stock is 1.4, which is read as a Strong Buy. 4 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. A total of 1 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.

Exelixis (EXEL) : 3 investment research analysts covering Exelixis (EXEL) have an average price target of $10.67 for the near short term. The highest target price given by the Brokerage Firm to the stock is $12 and the lowest target is $8 for the short term. Analysts expect the variance to be within $2.31 of the average price.


Shares of Exelixis, Inc. rose by 10.26% in the last five trading days and 33.3% for the last 4 weeks. Exelixis, Inc. is up 88.78% in the last 3-month period. Year-to-Date the stock performance stands at 105.85%. Exelixis (NASDAQ:EXEL): stock turned positive on Tuesday. Though the stock opened at $11.46, the bulls momentum made the stock top out at $11.7 level for the day. The stock recorded a low of $11.424 and closed the trading day at $11.61, in the green by 1.49%. The total traded volume for the day was 5,241,620. The stock had closed at $11.44 in the previous days trading.

Exelixis Inc. is a biopharmaceutical company. The Company is engaged in developing small molecule therapies for the treatment of cancer. The Company is focusing on resources development and commercialization of COMETRIQ (cabozantinib) for the treatment of progressive, metastatic medullary thyroid cancer (MTC) in the United States. The Companys other programs include metastatic renal cell carcinoma (mRCC), a phase III trial comparing cabozantinib to everolimus in patients with mRCC who have experienced disease progression following treatment with at least one prior VEGFR TKI; CELESTIAL, a phase III trial comparing cabozantinib with placebo in patients with advanced hepatocellular cancer (HCC) who have previously been treated with sorafenib; NSCLC (non-small cell lung cancer); mCRPC (metastatic castration-resistant prostate cancer) and XL888, a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *